Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Transcode Therapeutics (RNAZ)
Squarespace, Inc. (SQSP)
Procore Technologies, Inc. (PCOR)
Oatly Group Ab (OTLY)
Ziprecruiter, Inc. (ZIP)
Priced IPO
Save Foods (SVFD)
Vera Therapeutics, Inc. (VERA)
Digital Brands Group, Inc. (DBGI)
Ipower Inc. (IPW)
Global-e Online Ltd. (GLBE)
Similarweb Ltd. (SMWB)
Flora Growth (FLGC)
Anebulo Pharmaceuticals (ANEB)
Bowman Consulting Group Ltd. (BWMN)
Onion Global Limited (OG)
Waterdrop Inc. (WDH)
Talaris Therapeutics, Inc. (TALS)
Valneva Se (VALN)
Five Star Bancorp (FSBC)
The Honest Company Inc. (HNST)
Alfi, Inc. (ALF)
Red Cat Holdings (RCAT)
Werewolf Therapeutics Inc. (HOWL)
Vaccitech Plc. (VACC)
Endeavor Group Holdings (EDR)
More companies

Impel Neuropharma, Inc. (IMPL)

Sector - Healthcare

Price chart

-9.37%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a late-stage pharmaceutical company focused on utilizing their proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. Their strategy is to pair their proprietary Precision Olfactory Delivery upper nasal delivery technology with well-established therapeutics or other therapeutics where rapid vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within their target diseases. Since 2016, they have identified and advanced multiple product candidates, including TRUDHESATM (INP104) for the acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder. In November 2020, they submitted an NDA for TRUDHESA, for the acute treatment of migraine headaches with or without aura in adult patients. The FDA has filed and accepted the NDA for review and established a Prescription Drug User Fee Act goal date of September 6, 2021.
Industry
Pharmaceutical Preparations
CEO CFO
Adrian Adams John H. Leaman
Employees Founded
61 2008

Contacts

Address: 201 Elliott Avenue West, Suite 260 Seattle, Wa 98119

Telephone: (206) 568-1466

Web page: http://www.impelnp.com

IPO information

First Trade Date 4/23/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5.33
Shares Revised (MM) 5.33
Expected offer amount (MM) $79.95
Realized offer amount(MM) $79.95

Financial Data (last reporting year)

Market Cap (MM) $291.15
Revenues (MM) $0
Net Income (Loss) (MM) $-45.8

Voting

What do you think will happen with the IMPL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Cowen

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Cowen/ Guggenheim
CO-Managers
Wedbush PacGrow

Sector: Healthcare

Tweets about $IMPL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats